Pan Qiu-Zhong, Gu Jia-Mei, Zhao Jing-Jing, Tang Yan, Wang Qi-Jing, Zhu Qian, Song Meng-Jia, Li Yong-Qiang, He Jia, Chen Shi-Ping, Weng De-Sheng, Xia Jian-Chuan
State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat-Sen University Cancer Center Guangzhou China.
Department of Biotherapy Sun Yat-Sen University Cancer Center Guangzhou China.
Clin Transl Immunology. 2020 Feb 19;9(2):e1113. doi: 10.1002/cti2.1113. eCollection 2020.
Fluoropyrimidine-based chemotherapy regimens are the current first-line treatment for metastatic colorectal cancer (mCRC); however, the outcome is often unsatisfactory. The present study aimed to determine the effect of combined cytokine-induced killer (CIK) cell immunotherapy and first-line chemotherapy in patients with mCRC.
This retrospective study included 252 patients with mCRC treated with first-line chemotherapy. Among them, 126 patients received first-line chemotherapy only (control group), while the other 126 patients, with similar demographic and clinical characteristics, received CIK cell immunotherapy combined with first-line chemotherapy (CIK group). Overall survival (OS) and progression-free survival (PFS) were compared between the two groups using the Kaplan-Meier method.
The median OS for the CIK group was 54.7 versus 24.1 months for the controls, and the median PFS for the CIK group was 25.7 versus 14.6 months for the controls. Univariate and multivariate analyses indicated that CIK cell treatment was an independent prognostic factor for patients' OS and PFS. Subgroup analyses showed that CIK cell treatment significantly improved the OS and PFS of patients with metastatic colon cancer, but not those with metastatic rectal cancer. Additionally, the change in CD3CD56 subsets after the fourth treatment cycle might be an indicator of successful CIK cell treatment: Patients with increased CD3CD56 subsets had better survival than those with decreased CD3CD56 subsets.
Cytokine-induced killer cell immunotherapy combined with first-line chemotherapy could significantly improve the OS and PFS of patients with mCRC, particularly for patients with metastatic colon cancer.
基于氟尿嘧啶的化疗方案是目前转移性结直肠癌（mCRC）的一线治疗方法；然而，治疗效果往往不尽人意。本研究旨在确定细胞因子诱导的杀伤（CIK）细胞免疫疗法联合一线化疗对mCRC患者的疗效。
这项回顾性研究纳入了252例接受一线化疗的mCRC患者。其中，126例患者仅接受一线化疗（对照组），而另外126例具有相似人口统计学和临床特征的患者接受CIK细胞免疫疗法联合一线化疗（CIK组）。采用Kaplan-Meier法比较两组的总生存期（OS）和无进展生存期（PFS）。
CIK组的中位OS为54.7个月，而对照组为24.1个月；CIK组的中位PFS为25.7个月，而对照组为14.6个月。单因素和多因素分析表明，CIK细胞治疗是患者OS和PFS的独立预后因素。亚组分析显示，CIK细胞治疗显著改善了转移性结肠癌患者的OS和PFS，但对转移性直肠癌患者则不然。此外，第四个治疗周期后CD3CD56亚群的变化可能是CIK细胞治疗成功的一个指标：CD3CD56亚群增加的患者比CD3CD56亚群减少的患者生存期更长。
细胞因子诱导的杀伤细胞免疫疗法联合一线化疗可显著改善mCRC患者的OS和PFS，尤其是转移性结肠癌患者。
